The life science sector is heavily regulated and CTAs are some of the most important agreements for companies operating in this sector. Having appropriate CTAs in place is therefore essential for managing relationships between the different stakeholders, and apportioning risk and responsibilities between them. If appropriate contractual arrangements are not in place, a clinical trial may not receive approval or issues may arise with the integrity or validity of the data collected. Further, disputes between the parties can arise if responsibilities are not clearly defined in the agreement.
This intensive and interactive one-day programme focuses on CTAs in the pharmaceutical industry where legal, policy and ethical considerations underpin how these agreements are drafted. Participants will receive an overview of the legal framework regulating clinical trials in the European Union (and UK), before taking a closer, comprehensive look at specific issues that must be considered when drafting a CTA. Using a case study, participants will also look at some example clauses and will have the opportunity to practise negotiation skills in the safe environment of the course room under the guidance of our expert faculty.
By the end of the programme, you will be more confident in spotting and addressing the key issues that arise when negotiating and drafting CTAs, understand how best to mitigate against the risks and deal with them effectively when they do arise.
Key topics covered in this intensive and interactive seminar:
An overview of the legal, ethical and policy considerations that underpin the conduct clinical trials as these affect how the terms of clinical trials agreements are drafted
Recognising and dealing with key commercial and regulatory issues (including in particular relating to Brexit and the “flexibilities” adopted during the pandemic) that arise when drafting clinical trials agreements
Drafting and negotiating techniques to minimise disputes and maximise efficiency
Attending this seminar will enable you to:
- Understand the legal framework concerning clinical trials in the EU and the UK
- Recognise and address the issues that arise when drafting and negotiating CTAs
- Gain a better understanding of the commercial and regulatory issues that affect CTAs
- Consider the issues through the differing perspectives of sponsors and healthcare organisations
Please note:
- This event assumes that the attendees have familiarity with commercial contracts (and ideally clinical trial agreements and clinical investigation agreements).
- The speakers will explain the dynamic and increasingly demanding regulatory and data protection landscape to better inform those negotiations and drafting these agreements.
- The mock negotiations are aimed at people who want to obtain a better understanding of how to manage negotiations and to consider alternative approaches to common negotiation impasses.
Certification:
- CPD: 6 hours for your records
- Certificate of completion
Course Content
Course Provider
Mr Alex Denoon,
BristowsAlex Denoon is head of the regulatory team at Bristows, primarily advising life sciences clients. He has more than 20 years’ experience advising clients in the sector. In addition to his LLB, Alex has a BSc in Human Genetics. Alex spent more than five years in-house, including as GC and Company Secretary of Biotech Australia. He works with clients to devise and implement regulatory strategies throughout the product life cycle of pharmaceuticals and medical devices, and has advised clients in relation to more challenging issues including: genomics, cell therapies, tissue and cells requirements, borderline products, combination products, 3D printing, healthcare apps and remote diagnostics, and has been involved in the development of a number of regulatory frameworks and guidelines.
In addition to a range of contentious (judicial review) and advisory matters, he has a breadth of international experience in structuring, negotiating and drafting commercial agreements. Alex is widely published and speaks regularly at conferences.
Who Should Attend
- Contract managers
- Clinical contract specialists
- Clinical trial managers
- R&D staff
- Regulatory specialists
- Lawyers and in-house legal teams
- Legal executives